CannPal Animal Therapeutics Limited Market Research Report

Company Overview

• Name: CannPal Animal Therapeutics Limited

• Mission: To provide veterinarians and pet owners with innovative and naturally derived therapeutics to treat pets in a safe and ethical way.

• Vision: To be a global leader in the development of therapeutic products for companion animals using plant compounds that influence the endocannabinoid system.

• Founded: Not specified

• Founder(s): Not specified

• Key People: No information is available

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: CannPal is a global leader in the development of cannabinoid-derived therapeutic products aimed at providing veterinarians and pet owners with clinically validated and standardised therapies to treat animals in a safe and natural way.

Products

CannPal is developing products containing cannabinoids, specifically focusing on CBD and THC, and other active ingredients intended for registration and commercialisation as veterinary medicines and nutraceuticals, addressing issues such as pain, inflammation, mood, and dermatological conditions.

1. CPAT-01D (Pain Control in Dogs):

• Description: A cannabis-derived therapeutic product focused on controlling pain and inflammation in companion animals, particularly dogs.

• Key Features:

• Uses a proprietary combination of cannabinoids, CBD and THC.

• Offered in a standardized oral liquid formulation.

• Aims to secure regulatory approval for safer, cGMP-produced cannabinoid-derived treatments.

2. DermaCann (Canine Skin Health):

• Description: Aimed at promoting optimal skin health in dogs by addressing allergic skin conditions using hemp-derived compounds.

• Key Features:

• Utilizes hemp plant compounds, rich in Omega 3 and 6, plus proprietary ingredients.

• Targets skin diseases prevalent in companion animals.

Recent Developments

• New Product Launches: No specific new product launches mentioned.

• New Features Added: No specific features added to existing products mentioned.

• New Partnerships:

• CSIRO Collaboration: In partnership with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) under the CSIRO Kick-Start initiative, focusing on enhanced delivery systems for active ingredients across their therapeutic products.

The focus of CannPal's development is on addressing clear unmet needs in the companion animal market using cannabinoid-derived therapeutics. The company is recognized for exploring the natural healing abilities of compounds that target the endocannabinoid system, aiming to improve therapeutic outcomes without negative side effects. Their product pipeline prioritizes developing treatment alternatives for common conditions such as pain, inflammation, and skin health in animals.